OpGen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPGN research report →
Range $0.67 – $0.67
Price Chart
About the company
OpGen, Inc. is a precision medicine company dedicated to developing and commercializing advanced molecular microbiology solutions for both U. S.
- CEO
- Christian-Laurent Benoit Bonte
- IPO
- 2015
- Employees
- 85
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on OPGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $242.67M
- P/E
- 0.74
- PEG
- 0.01
- P/S
- 0.55
- P/B
- 0.67
- EV/EBITDA
- 0.67
- Div Yield
- 0.00%
- Gross Margin
- 89.53%
- Op Margin
- 84.82%
- Net Margin
- 81.73%
- ROE
- 168.84%
- ROIC
- 83.36%
Latest fiscal year · YoY change
- Revenue
- $30.20M+481.2%
- Gross Profit
- $27.18M+426.4%
- Op Income
- $24.03M
- Net Income
- $23.62M+97.0%
- EPS
- $2.33-4.5%
- OCF Growth
- +75.7%
- FCF Growth
- +75.7%
- 52W High
- $34.00
- 52W Low
- $0.00
- 50D MA
- $22.24
- 200D MA
- $8.61
- Beta
- -1.93
- RSI (14)
- 50
- Avg Volume
- 5.58K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
OpGen said Q2 revenue fell year over year, but highlighted new commercial contracts and partnership progress while warning it may not have enough cash to fund operations beyond September 2023.· August 10, 2023
- Q2 revenue was $736,000, down from $967,000 a year ago; H1 2023 revenue was about $1.65 million, up about 15% year over year.
- Operating expenses declined to $5.9 million in Q2 from $6.2 million, driven mainly by lower R&D spending.
- Cash ended June 30, 2023 at about $3.2 million, and management said current cash is not expected to fund operations beyond September 2023.
- The company raised $3.5 million in a public offering in early May and is pursuing debt restructuring, new capital, asset sales, and other alternatives.
- Management pointed to new U.S. distribution and customer wins, plus progress on FIND, FDA, and China-related programs, but took no questions on the call.
OpGen reported second-quarter 2023 revenue of approximately $736,000 versus $967,000 in Q2 2022. First-half 2023 revenue was approximately $1.65 million, up about 15% from approximately $1.44 million in the first half of 2022. Total operating expenses were $5.9 million in Q2 versus $6.2 million a year ago; R&D was $1.4 million versus $2.3 million, G&A was $2.4 million versus $2.1 million, and sales and marketing was about $1.2 million, unchanged year over year. Cash was approximately $3.2 million at June 30, 2023, down from about $7.4 million at the end of 2022. Management said it does not expect current cash to fund operations beyond September 2023 and reiterated substantial doubt about continuing as a going concern. For the FIND collaboration, the next phase has an assigned budget of up to approximately $600,000, with the first payment of about $200,000 due on signing and the remainder in two equal tranches over the coming three quarters. Management also said recent commercial contracts totaled potential annualized revenue volume of up to $1.5 million.
Oliver Schacht emphasized commercialization across OpGen’s platforms, saying the company saw traction in the quarter and had several successful recent commercial contract signings. He highlighted progress on FIND, the FDA de novo request for Unyvero UTI, a U.S. distribution deal with Fisher Healthcare, and continued China partnership efforts for Unyvero A50 and A30. His tone was constructive on business momentum, but the overall message was tempered by the financing pressure discussed on the call.
Albert Weber focused on the financial decline in quarterly revenue, the modest first-half growth, and expense discipline. He noted Q2 operating expenses fell to $5.9 million from $6.2 million, with R&D down 39% to $1.4 million, while cash ended at about $3.2 million after a $3.5 million public offering in May. He also said a second EIB debt tranche was partially paid with $1 million in June under a standstill agreement through November 30, 2023, and reiterated that the company may need restructuring, refinancing, or additional capital to keep operating.
There was no Q&A on the call, so no analyst questions or management answers were taken live. The most notable concerns raised came from management’s own prepared remarks, especially the warning that cash may not last beyond September 2023 and that there is substantial doubt about the company’s ability to continue as a going concern. Management said it is evaluating debt restructuring, financing, asset sales, and other strategic alternatives, but offered no assurance any will succeed.
The bullish case from this call is that OpGen is building visible commercial momentum across Unyvero, Acuitas, and Ares, including several new U.S. contracts and a Fisher Healthcare distribution partnership that could expand reach. Management also pointed to continued progress with FIND, FDA review of Unyvero UTI, and a defended European patent, all of which support future monetization opportunities.
The main bear case is liquidity: management explicitly said current cash is not expected to fund operations beyond September 2023 and raised substantial doubt about going concern. Revenue was lower in Q2 year over year, and the company still depends on successful execution of financing, debt restructuring, and commercialization to convert the cited pipeline into sustained cash flow.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 15.8%
- Shares Outstanding
- 10.15M
- Float Shares
- 1.61M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ladenburg Thalmann Financial Services Inc. | 6 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 23, 26 | Lim Zhao Qi Ken | other | 5,555 |
| Feb 23, 26 | Yee Gillian Tan Rou | other | 2,778 |
| Nov 8, 22 | Schlaeppi Yvonne | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OPGN coverage
Recent articles, reports, and earnings notes.
No research on OPGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPGN report →OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
globenewswire.com · Feb 27
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
investorplace.com · Aug 21
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
investorplace.com · Jun 5
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
globenewswire.com · May 24
OpGen Announced 1-for-10 Reverse Stock Split
globenewswire.com · May 16
OpGen Provides Update on Business Operations and Strategic Opportunities
globenewswire.com · Apr 29
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
globenewswire.com · Apr 23
OpGen Announces Acquisition of Preferred Stock by David Lazar
globenewswire.com · Mar 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.